Author: Janis H. Jenkins
Publisher:
ISBN: 9781934691380
Category : Drug accessibility
Languages : en
Pages : 0
Book Description
Exploring such questions as how our culturally constituted selves are transformed by regular ingestion of psychopharmacological drugs, this volume addresses a critical contemporary issue - the worldwide proliferation of pharmaceutical use.
Pharmaceutical Self
Author: Janis H. Jenkins
Publisher:
ISBN: 9781934691380
Category : Drug accessibility
Languages : en
Pages : 0
Book Description
Exploring such questions as how our culturally constituted selves are transformed by regular ingestion of psychopharmacological drugs, this volume addresses a critical contemporary issue - the worldwide proliferation of pharmaceutical use.
Publisher:
ISBN: 9781934691380
Category : Drug accessibility
Languages : en
Pages : 0
Book Description
Exploring such questions as how our culturally constituted selves are transformed by regular ingestion of psychopharmacological drugs, this volume addresses a critical contemporary issue - the worldwide proliferation of pharmaceutical use.
Pharmaceutical Freedom
Author: Jessica Flanigan
Publisher: Oxford University Press
ISBN: 0190684542
Category : Law
Languages : en
Pages : 289
Book Description
Jessica Flanigan defends patients' rights of self-medication on the grounds that same moral reasons against medical paternalism in clinical contexts are also reasons against paternalistic pharmaceutical policies, including prohibitive approval processes and prescription requirements.
Publisher: Oxford University Press
ISBN: 0190684542
Category : Law
Languages : en
Pages : 289
Book Description
Jessica Flanigan defends patients' rights of self-medication on the grounds that same moral reasons against medical paternalism in clinical contexts are also reasons against paternalistic pharmaceutical policies, including prohibitive approval processes and prescription requirements.
Drug Safety in Developing Countries
Author: Yaser Mohammed Al-Worafi
Publisher: Academic Press
ISBN: 0128204125
Category : Medical
Languages : en
Pages : 656
Book Description
Drug Safety in Developing Countries: Achievements and Challenges provides comprehensive information on drug safety issues in developing countries. Drug safety practice in developing countries varies substantially from country to country. This can lead to a rise in adverse reactions and a lack of reporting can exasperate the situation and lead to negative medical outcomes. This book documents the history and development of drug safety systems, pharmacovigilance centers and activities in developing countries, describing their current situation and achievements of drug safety practice. Further, using extensive case studies, the book addresses the challenges of drug safety in developing countries. - Provides a single resource for educators, professionals, researchers, policymakers, organizations and other readers with comprehensive information and a guide on drug safety related issues - Describes current achievements of drug safety practice in developing countries - Addresses the challenges of drug safety in developing countries - Provides recommendations, including practical ways to implement strategies and overcome challenges surrounding drug safety
Publisher: Academic Press
ISBN: 0128204125
Category : Medical
Languages : en
Pages : 656
Book Description
Drug Safety in Developing Countries: Achievements and Challenges provides comprehensive information on drug safety issues in developing countries. Drug safety practice in developing countries varies substantially from country to country. This can lead to a rise in adverse reactions and a lack of reporting can exasperate the situation and lead to negative medical outcomes. This book documents the history and development of drug safety systems, pharmacovigilance centers and activities in developing countries, describing their current situation and achievements of drug safety practice. Further, using extensive case studies, the book addresses the challenges of drug safety in developing countries. - Provides a single resource for educators, professionals, researchers, policymakers, organizations and other readers with comprehensive information and a guide on drug safety related issues - Describes current achievements of drug safety practice in developing countries - Addresses the challenges of drug safety in developing countries - Provides recommendations, including practical ways to implement strategies and overcome challenges surrounding drug safety
Making Medicines Affordable
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Ending Discrimination Against People with Mental and Substance Use Disorders
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309439124
Category : Social Science
Languages : en
Pages : 171
Book Description
Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.
Publisher: National Academies Press
ISBN: 0309439124
Category : Social Science
Languages : en
Pages : 171
Book Description
Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.
Drugs for Life
Author: Joseph Dumit
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Pharmaceutical Analysis E-Book
Author: David G. Watson
Publisher: Elsevier Health Sciences
ISBN: 0702069884
Category : Medical
Languages : en
Pages : 598
Book Description
Pharmaceutical analysis determines the purity, concentration, active compounds, shelf life, rate of absorption in the body, identity, stability, rate of release etc. of a drug. Testing a pharmaceutical product involves a variety of chemical, physical and microbiological analyses. It is reckoned that over £10 billion is spent annually in the UK alone on pharmaceutical analysis, and the analytical processes described in this book are used in industries as diverse as food, beverages, cosmetics, detergents, metals, paints, water, agrochemicals, biotechnological products and pharmaceuticals. This is the key textbook in pharmaceutical analysis, now revised and updated for its fourth edition. Worked calculation examples Self-assessment Additional problems (self tests) Practical boxes Key points boxes New chapter on electrochemical biosensors. New chapter on the quality control of biotechnologically produced drugs. Extended chapter on molecular emission spectroscopy. Now comes with an e-book on StudentConsult. Self-assessment is interactive in the accompanying online e-book. 65 online animations show concepts such as ionization partitioning of drug molecules etc. ~
Publisher: Elsevier Health Sciences
ISBN: 0702069884
Category : Medical
Languages : en
Pages : 598
Book Description
Pharmaceutical analysis determines the purity, concentration, active compounds, shelf life, rate of absorption in the body, identity, stability, rate of release etc. of a drug. Testing a pharmaceutical product involves a variety of chemical, physical and microbiological analyses. It is reckoned that over £10 billion is spent annually in the UK alone on pharmaceutical analysis, and the analytical processes described in this book are used in industries as diverse as food, beverages, cosmetics, detergents, metals, paints, water, agrochemicals, biotechnological products and pharmaceuticals. This is the key textbook in pharmaceutical analysis, now revised and updated for its fourth edition. Worked calculation examples Self-assessment Additional problems (self tests) Practical boxes Key points boxes New chapter on electrochemical biosensors. New chapter on the quality control of biotechnologically produced drugs. Extended chapter on molecular emission spectroscopy. Now comes with an e-book on StudentConsult. Self-assessment is interactive in the accompanying online e-book. 65 online animations show concepts such as ionization partitioning of drug molecules etc. ~
The Professional Guinea Pig
Author: Roberto Abadie
Publisher: Duke University Press Books
ISBN: 9780822348146
Category : Social Science
Languages : en
Pages : 0
Book Description
The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified “professional guinea pigs” in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials.
Publisher: Duke University Press Books
ISBN: 9780822348146
Category : Social Science
Languages : en
Pages : 0
Book Description
The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified “professional guinea pigs” in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials.
Living Pharmaceutical Lives
Author: Peri Ballantyne
Publisher: Routledge
ISBN: 1000384004
Category : Medical
Languages : en
Pages : 216
Book Description
Increasingly, pharmaceuticals are available as the solutions to a wide range of human health problems and health risks, minor and major. This book portrays how pharmaceutical use is, at once, a solution to, and a difficulty for, everyday life. Exploring lived experiences of people at different stages of the life course and from different countries around the world, this collection highlights the benefits as well as the challenges of using medicines on an everyday basis. It raises questions about the expectations associated with the use of medications, the uncertainty about a condition or about the duration of a medicine regimen for it, the need to negotiate the stigma associated with a condition or a type of medicine, the need to access and pay for medicines and the need to schedule medicine use appropriately, and the need to manage medicines’ effects and side effects. The chapters include original empirical research, literature review and theoretical analysis, and convey the sociological and phenomenological complexity of ‘living pharmaceutical lives’. This book is of interest to all those studying and researching social pharmacy and the sociology of health and illness.
Publisher: Routledge
ISBN: 1000384004
Category : Medical
Languages : en
Pages : 216
Book Description
Increasingly, pharmaceuticals are available as the solutions to a wide range of human health problems and health risks, minor and major. This book portrays how pharmaceutical use is, at once, a solution to, and a difficulty for, everyday life. Exploring lived experiences of people at different stages of the life course and from different countries around the world, this collection highlights the benefits as well as the challenges of using medicines on an everyday basis. It raises questions about the expectations associated with the use of medications, the uncertainty about a condition or about the duration of a medicine regimen for it, the need to negotiate the stigma associated with a condition or a type of medicine, the need to access and pay for medicines and the need to schedule medicine use appropriately, and the need to manage medicines’ effects and side effects. The chapters include original empirical research, literature review and theoretical analysis, and convey the sociological and phenomenological complexity of ‘living pharmaceutical lives’. This book is of interest to all those studying and researching social pharmacy and the sociology of health and illness.
Inventing Disease and Pushing Pills
Author: Jörg Blech
Publisher: Taylor & Francis
ISBN: 1000938573
Category : Medical
Languages : en
Pages : 148
Book Description
This is a highly accessible and reassuring account of how the pharmaceutical industry is redefining health, making it a state that is almost impossible to achieve. Many normal life processes – states as natural as birth, ageing, sexuality, unhappiness and death – are systematically being reinterpreted as pathological so creating new markets for their treatments. In this enlightening book, Jörg Blech reveals: how the invention of diseases by pharmaceutical companies is turning us all into patients, and how we can protect ourselves against this how the medical profession has been bullied and co-opted into endorsing profitable cures for people who aren't ill fears about how pharmaceutical companies create markets by playing on the general public's concern with their health A self-help book in the truest sense, Inventing Disease and Pushing Pills reassures us about our own health. It is essential reading for doctors, nurses and patients alike.
Publisher: Taylor & Francis
ISBN: 1000938573
Category : Medical
Languages : en
Pages : 148
Book Description
This is a highly accessible and reassuring account of how the pharmaceutical industry is redefining health, making it a state that is almost impossible to achieve. Many normal life processes – states as natural as birth, ageing, sexuality, unhappiness and death – are systematically being reinterpreted as pathological so creating new markets for their treatments. In this enlightening book, Jörg Blech reveals: how the invention of diseases by pharmaceutical companies is turning us all into patients, and how we can protect ourselves against this how the medical profession has been bullied and co-opted into endorsing profitable cures for people who aren't ill fears about how pharmaceutical companies create markets by playing on the general public's concern with their health A self-help book in the truest sense, Inventing Disease and Pushing Pills reassures us about our own health. It is essential reading for doctors, nurses and patients alike.